Due to increased circulatory CXCL2 and CXCL5 levels, AA men likely acquire a disadvantage with vulnerable immune surveillance, leading to aggressive prostate cancer, as often seen in AA men at diagnosis. This evidence concerns the gene CXCL2 and prostate cancer.